Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers-Reference-Cited by-同舟云学术

Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers

Published:2016-08-05 Issue:9 Volume:7 Page:1201-1211
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Niswender Colleen M.,Jones Carrie K.,Lin Xin¹,Bubser Michael,Thompson Gray Analisa,Blobaum Anna L.,Engers Darren W.,Rodriguez Alice L.,Loch Matthew T.,Daniels J. Scott,Lindsley Craig W.,Hopkins Corey R.,Javitch Jonathan A.¹,Conn P. Jeffrey

Affiliation:

1. Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States

Funder

National Institute of Neurological Disorders and Stroke

Bristol-Myers Squibb

Michael J. Fox Foundation for Parkinson's Research

National Institute on Drug Abuse

National Institute of Mental Health

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine